Thus, aminoglycoside liposomes Improved bactericidal effects over conventional treatment in disseminated MAC infection, offering potential application in treating MAC infection in humans. (amikacin, cefoxitin/imipenem and/or tigecycline) with oral macrolides. However, the rates of default and disease recurrence after treatment completion are still high.
#Amikin for mac disease free#
Equivalent doses of free drug were not associated with significant decreases in viable bacteria. The clinical relevance of reinfection MAC isolates must be individually. of MAC pulmonary disease and should be maintained for at least 12 months after negative sputum culture conversion.
This drug is either amikacin (Amikin, by Sicor Pharmaceuticals) or. Amikacin and gentamicin liposomes significantly reduced bacterial counts in blood, liver, and spleen (98.5%, 92.7%, and 92.8%, respectively, for the 1-mg dose of amikacin and 92%, 99.7%, and 99.4% for gentamicin 95.7%, 69.79%, and 89.1%, respectively, for the 0.2-mg dose of amikacin and 49.9%, 76.7%, and 89.1% for gentamicin) compared with placebo liposomes and buffer. Disseminated MAC disease frequently occurs in AIDS patients due to a very low immune. To examine whether liposome-encapsulated aminoglycosides might kill intracellular MAC more effectively in vivo, beige mice were infected with MAC strain 101 (serotype 1) and after 1 week were treated intravenously every other day (5 doses total) with amikacin liposomes (0.2, 1, or 4 mg/dose), amikacin solution (0.2, 1, Or 2 mg), gentamicin liposomes or gentamicin solution (0.2 or 1 mg), placebo liposomes (without aminoglycosides), or buffer. Free and liposome-encapsulated amikacin are active in vitro against intracellular Mycobacterium avium complex (MAC).
0 kommentar(er)
